SRPTSarepta Therapeutics Inc
SRPT
Sarepta Therapeutics Inc26,730
Mkt Cap
$1.72BVolume
3.35M52W High
$138.8152W Low
$10.42PE Ratio
-5.67SRPT Fundamentals
Price
$16.56Prev Close
$16.39Open
$16.5850D MA
$20.23Beta
1.05Avg. Volume
5.2MEPS (Annual)
$2.34P/B
1.30Rev/Employee
$1.39MSarepta Therapeutics (NASDAQ:SRPT) Stock Price Down 5.3% - What's Next?
Sarepta Therapeutics (NASDAQ:SRPT) Shares Down 5.3% - Time to Sell...
MarketBeat·3h ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...
PR Newswire·5h ago
Raiffeisen Bank International AG Has $723,000 Stock Position in Sarepta Therapeutics, Inc. $SRPT
Raiffeisen Bank International AG boosted its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 137.4% in the second quarter, according to the company in its most recent disclosure...
MarketBeat·9h ago
Bank of New York Mellon Corp Sells 641,805 Shares of Sarepta Therapeutics, Inc. $SRPT
Bank of New York Mellon Corp decreased its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 49.7% during the second quarter, according to its most recent filing with the...
MarketBeat·12h ago
FDA Restricts Use of Sarepta's Gene Therapy, Adds Safety Warnings
SRPT's Elevidys gets a sharply narrowed FDA label with new liver safety warnings that reshape how the gene therapy can be used.
Zacks·3d ago
Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Up 8% - Time to Buy?
Sarepta Therapeutics (NASDAQ:SRPT) Shares Up 8% - Here's Why...
MarketBeat·4d ago
2 Beaten-Down Stocks to Avoid Right Now
Key PointsIntellia Therapeutics and Sarepta Therapeutics have hit serious setbacks potentially linked to their treatments...
Nasdaq News: Markets·5d ago
Sarepta Shares Jump After FDA Approves Updated Elevidys Label
Sarepta Therapeutics shares jumped after the FDA issued a new boxed warning for Elevidys.read more...
Benzinga·6d ago
Sarepta Announces FDAs Approval of Updated ELEVIDYS Prescribing Information
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced an update to the prescribing information for ELEVIDYS (delandistrogene...
Business Wire·6d ago